Last updated: March 3, 2025
Sponsor: Damascus University
Overall Status: Completed
Phase
1/2
Condition
Vascular Diseases
Circulation Disorders
Stress
Treatment
Sildenafil
Vardenafil
Clinical Study ID
NCT06860399
UDMS-Pediatrics-2025-01
20230501
Ages 24-96 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Gestation age: 28 weeks or more
Exclusion
Exclusion Criteria:
- Cardiac deformity, inability to administer the drug orally
Study Design
Total Participants: 55
Treatment Group(s): 2
Primary Treatment: Sildenafil
Phase: 1/2
Study Start date:
May 01, 2023
Estimated Completion Date:
September 30, 2024
Study Description
Connect with a study center
Children's Hospital
Damascus, 011
Syrian Arab RepublicSite Not Available

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.